Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis

– OpSCF is a novel monoclonal antibody directed against the inflammatory form of stem cell factor

See more here


Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

QTORIN™ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations

Microcystic Lymphatic Malformations is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 patients in the U.S.

See more here


SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma

See more here


Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

Funds to support advancement of lead candidate, VIPER-101, to the clinic

See more here


VESTECK, Inc. “it is always someone’s mom or dad, brother or sister.”

See more here


ONCO, Inc. Announces Strategic Partnership with Oncora Medical to Launch Data-Driven Software Automation to Enhance Patient Care and Oncology Data Management.

See more here


Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.

See more here


Immunome Reports Third Quarter 2023 Financial Results

Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors

Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO

Bob Lechleider, M.D., appointed as Chief Medical Officer

Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors

Cash runway expected to extend into Q1 2026*

See more here


Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

– Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors

See more here


ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023

– ENB-003 in combination with KEYTRUDA (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC)

– Encouraging results support further development

– Expansion cohort in primary PROC and other refractory advanced cancers (ENB-003 + KEYTRUDA) to commence in 2024

See more here